secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K/A
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063774
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics raises $67.154M in Series A-1 Preferred; restructures warrant tranches
--------------------------------------------------------------------------------

- Initially issued 7,500 Series A-1 Preferred shares for $7.5M on Oct 2, 2023.
- Exercised Tranche A warrants: 59,654 additional shares for $59.654M by Nov 14.
- Investors assumed 16,269 unexercised warrants; received new Tranche B and C warrants.
- Outstanding now: 42,846 Tranche B warrants ($42.846M) and 107,115 Tranche C warrants ($107.115M).
- Unexercised Tranche A warrants and remaining Tranche B/C warrants cancelled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023063774/0000950170-23-063774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023063774/sabs-20230929.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer